InvestWiser

Devyser Diagnostics AB

DVYSRNasdaq StockholmHealthcareMarket value 1.1 bn SEK
62.80SEK −2.2%
last day · Price as of 18 November 2026

The answer first

Does Devyser Diagnostics beat the market?

No, Devyser Diagnostics has not beaten the market over the last year.

Devyser Diagnostics−42.4%Stockholm (OMXSGI)+18.7%
  • The ranking · Quality, value and trend combined

    Better than 38% of Nordic stocks

    • Quality89
    • Value24
    • Trend23

    No. 85 of 195 in healthcare

  • Expectations in the price

    High expectations

    For the share to return about 9% a year from today's price, the cash Devyser Diagnostics keeps must grow about 9% a year for 10 years.

Max for seven days

Follow Devyser Diagnostics with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Devyser Diagnostics

From today, at a price of 62.80 SEK. Write why you follow Devyser Diagnostics, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Devyser Diagnostics

Your first answer is free, no account needed.

Do you own Devyser Diagnostics, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Devyser Diagnostics and a few more. Free, no card.

Past year against the exchange and Super Stock
Devyser Diagnostics−42.4%Stockholm (OMXSGI)+18.7%Super Stock+45.9%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Devyser Diagnostics has fallen 42.4% over the past year, including dividends.
  • Overall, Devyser Diagnostics ranks better than 38% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 68.5%. The price is 60.0% below its peak now.

What do analysts think of Devyser Diagnostics?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

38

Quality, value and trend together. Better than 38% of Nordic stocks.

No. 85 of 195 in healthcare

Quality89
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 35 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.15
  • Asset turnoverSales divided by everything the company owns0.51
  • Return on equityProfit divided by equity+6.5%
  • Cash conversionOperating cash flow divided by profit2.29

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value24
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 88 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50

  • P/BPrice divided by equity2.7
  • P/SPrice divided by sales4.1
  • P/EPrice divided by earnings41.2
  • P/CFPrice divided by operating cash flow18.2

The ranking is built on P/E, P/B and P/S.

Trend23
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 117 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+3.3%
  • 6 months−34.6%
  • 9 months−34.9%
  • 12 months−42.4%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+24.4%
3 years, per year
+1.8%
5 years, per year
–
Year to date
−45.0%
Largest fall, 3 years
−68.5%
From a peak to the bottom
From the peak now
−60.0%
How far the price is from the peak
Volatility, 1 year
50.1%
How much the price swings over a year
Beta, 1 year
0.67
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Devyser Diagnostics

8 funds we follow own Devyser Diagnostics. The share is how much of the fund the stock makes up.

  • Sweden8

From the funds' latest known holdings.

About Devyser Diagnostics

Devyser Diagnostics AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 110 employees.

Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results. The company was incorporated in 2004 and is headquartered in Årsta, Sweden.

See the full analysis of Devyser Diagnostics.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market